Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the National Cancer Institute of Canadia Clinical Trials Group

Current Oncology

Volumn 15, Issue 4, 2008, Pages 14-19

  Parulekar, Wendy R ^a   McKenzie, M ^b   Chi, K N ^b   Klotz, L ^c   Catton, C ^d   Brundage, M ^e   Ding, K ^a   Hiltz, A ^a   Meyer, R ^a   Saad, F ^f  

^a Queen's Cancer Research Institute   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e KINGSTON GENERAL HOSPITAL   (Canada)

^f NOTRE DAME HOSPITAL   (Canada)

Author keywords

Clinical trials; Localized prostate cancer; Risk estimation

Indexed keywords

ANTIANDROGEN; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; CANADA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DIARRHEA; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; FEBRILE NEUTROPENIA; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PATIENT CARE; POSTOPERATIVE CARE; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RADIATION SICKNESS; RESPIRATORY TRACT DISEASE; REVIEW; SKIN MANIFESTATION; TREATMENT RESPONSE; VASCULAR DISEASE;

EID: 54349090092     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto: Canadian Cancer Society; 2007.
2. Draisma C, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
3. Etzoni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
4. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
5. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467-71.
6. Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
7. Klotz L. Active surveillance for favorable risk prostate cancer: rationale, risks, and results. Urol Oncol 2007;25:505-9.
8. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-8.
9. Hanks GE, Pajak TF, Porter A, et al. on behalf of the Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8.
10. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90.
11. Canadian Pharmacists Association (CPhA). Compendium of Pharmaceuticals and Specialties 2007: The Canadian Drug Reference for Health Professionals. Ottawa: CPhA; 2007.
12. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
13. Tannock IF, de Wit R, Berry WR, et al. on behalf of the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
14. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63:1138-42.
15. Berger AP, Niescher M, Fischer-Colbrie R, Pelzer A, Bartsch G, Horninger W. Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers. Urol Int 2004;73:110-12.
16. Hussain A, Dawson N, Amin P, et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005;23:2789-96.
17. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-40.
18. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
19. Friedland D, Cohen J, Miller R, et al. A phase II trial of Taxotere in hormone refractory prostate cancer: correlation of antitumour activity to phosphorylation of Bcl-2 [abstract 1237]. Proc Am Soc Clin Oncol 1999;18:. [Available online at: www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview= abst_detail_view&confID=17&abstractID=15490; cited May 8, 2008]
20. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000;6:1655-63.
21. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of Bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-45.
22. Eigl BJ, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005;11:4905-11.
23. Winquist E, Chi KN, Chin J, et al. Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCAP): pathologic outcomes and 3-year follow-up analyses [abstract 5002]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=47&abstractID= 30613; cited May 8, 2008]
24. McKenzie MR, Chi KN, Neville A, et al. Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCAP) [abstract 4631]. Proc Am Soc Clin Oncol 2006;24:. [Available online at: www.asco.org/ASCO/Abstracts+%2 6+Virtual+Meeting/Abstracts?&vmview= abst_detail_view&confID=40&abstractID=34492; cited May 8, 2008]
25. Hodgson D, Urbach D, Przybysz R, Gong Y, Sullivan T, Rabeneck L. Cancer surgery. Chapter 2. In: Tu JV, Pinfold SP, McColgan P, Laupacis A, eds. Access to Health Services in Ontario. Toronto: Institute for Clinical Evaluative Sciences; April 2005: 10. [Available online at: www.ices.on.ca/WebBuild/site/ices-internet-upload/file_collection/ Chp2_v5new.pdf; cited June 9, 2008]
26. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-8.
27. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35.
28. Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (ws) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/ 95) [abstract 5060]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts? &vmview=abst_detail_view&confID=47&abstractID=35176; cited May 8, 2008]
29. Morris SL, Parker C, Huddart R, Horwich A, Dearnaley D. Current opinion on adjuvant and salvage treatment after radical prostatectomy. Clin Oncol (R Coll Radiol) 2004;16:277-82.
30. Lee LW, Clarke NW, Ramani VA, Cowan RA, Wylie JP, Logue JP. Adjuvant and salvage treatment after radical prostatectomy: current practice in the U.K. Prostate Cancer Prostatic Dis 2005;8:229-34.